-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $35

Benzinga·12/16/2025 16:08:22
語音播報
JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $28 to $35.